Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Study: new drug doesn't display cross-resistance.

AIDS alert - 1 Jul 1999

Abstract excerpt

Agenerase (amprenavir), the first of a new generation of protease inhibitors, manufactured by Glaxo Wellcome, promises to be a powerful drug for salvage therapy and for use in treatment-naive patients. It is the first protease inhibitor to be approved by the Rockville, MD-based Food and Drug Administration in 2 years. The drug does not elevate glucose or triglyceride levels as much as some of the other protease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Clinical Trials as Topic
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Furans

Share to HIV Protease Inhibitors

Share to Salvage Therapy

Share to Sulfonamides

Source

Identifiers

PMID: 11366418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Study: new drug doesn't display cross-resistance.PMID 11366418Read ↗

Protease inhibitors: resistance, resistance, resistance.Semantic proximity Read ↗

New drugs-reports of new drugs recently approved by the FDA. Abacavir sulfate.Semantic proximity Read ↗

The medical merry-go-round: drugs for 1998 are new but not novel.Semantic proximity Read ↗

Telaprevir to boceprevir switch highlights lack of cross-reactivity.Semantic proximity Read ↗

Cross-resistance within the protease inhibitor class.Semantic proximity Read ↗

Roche investigators say Invirase does not cause cross-resistance to other protease inhibitors.Semantic proximity Read ↗

Protease inhibitors: drug resistance and cross resistance overview.Semantic proximity Read ↗

Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy.Semantic proximity Read ↗

Emivirine: an NRTI that functions as an NNRTI.Semantic proximity Read ↗

New nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.